Glucagon-like peptide-1 enhances cardiac L-type Ca2+ currents via activation of the cAMP-dependent protein kinase A pathway

Cardiovascular Diabetology

Volumn 10, Issue , 2011, Pages

  Xiao, Yong Fu ^a   Nikolskaya, Alena ^a   Jaye, Deborah A ^a   Sigg, Daniel C ^a  

^a MEDTRONIC INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL L TYPE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; EXENDIN (9 39); EXENDIN (9-39); GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 (7 36)AMIDE; GLUCAGON LIKE PEPTIDE RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE 1 (7-36)AMIDE; GLUCAGON-LIKE PEPTIDE RECEPTOR; PEPTIDE FRAGMENT; PROTEIN KINASE INHIBITOR;

ACTION POTENTIAL; ANIMAL CELL; ARTICLE; CALCIUM CURRENT; DOG; ENZYME INHIBITION; HEART LEFT VENTRICLE; HEART MUSCLE CELL; NONHUMAN; PATCH CLAMP; REPOLARIZATION; ANIMAL; CALCIUM SIGNALING; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; IN VITRO STUDY; METABOLISM; TIME;

ACTION POTENTIALS; ANIMALS; CALCIUM CHANNELS, L-TYPE; CALCIUM SIGNALING; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DOGS; ENZYME ACTIVATION; GLUCAGON-LIKE PEPTIDE 1; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; PEPTIDE FRAGMENTS; PROTEIN KINASE INHIBITORS; RECEPTORS, GLUCAGON; TIME FACTORS;

EID: 78651589386     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-10-6     Document Type: Article

References (48)

1. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987, 2:1300-4. 10.1016/S0140-6736(87)91194-9, 2890903.
2. Orskov C, Wettergren A, Holst JJ. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 1993, 42:658-61. 10.2337/diabetes.42.5.658, 8482423.
3. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993, 214:829-35. 10.1111/j.1432-1033.1993.tb17986.x, 8100523.
4. Runge S, Thogersen H, Madsen K, Lau J, Rudolph R. Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain. J Biol Chem 2008, 283:11340-7. 10.1074/jbc.M708740200, 18287102.
5. Kavianipour M, Ehlers MR, Malmberg K, Ronquist G, Ryden L, Wikstrom G, et al. Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides 2003, 24:569-78. 10.1016/S0196-9781(03)00108-6, 12860201.
6. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004, 110:955-61. 10.1161/01.CIR.0000139339.85840.DD, 15313949.
7. Luque MA, Gonzalez N, Marquez L, Acitores A, Redondo A, Morales M, et al. Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes. J Endocrinol 2002, 173:465-73. 10.1677/joe.0.1730465, 12065236.
8. Barragan JM, Rodriguez RE, Blazquez E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am J Physiol 1994, 266:E459-66.
9. Barragan JM, Rodriguez RE, Eng J, Blazquez E. Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats. Regul Pept 1996, 67:63-8. 10.1016/S0167-0115(96)00113-9, 8952007.
10. Holz GG, Heart E, Leech CA. Synchronizing Ca2+ and cAMP oscillations in pancreatic beta-cells: a role for glucose metabolism and GLP-1 receptors? Focus on "regulation of cAMP dynamics by Ca2+ and G protein-coupled receptors in the pancreatic beta-cell: a computational approach". Am J Physiol Cell Physiol 2008, 294:C4-6. 10.1152/ajpcell.00522.2007, 17989206.
11. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109:962-5. 10.1161/01.CIR.0000120505.91348.58, 14981009.
12. Bose AK, Mocanu MM, Carr RD, Yellon DM. Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther 2005, 19:9-11. 10.1007/s10557-005-6892-4, 15883751.
13. Vila Petroff MG, Egan JM, Wang X, Sollott SJ. Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. Circ Res 2001, 89:445-52. 10.1161/hh1701.095716, 11532906.
14. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117:2340-50. 10.1161/CIRCULATIONAHA.107.739938, 18427132.
15. Madsbad S. Clinical Trial Report-Liraglutide Effect and Action in Diabetes (LEAD™) trial. Expert Review of Endocrinology & Metabolism 2009, 4:119-29.
16. McClenaghan NH, Flatt PR, Ball AJ. Actions of glucagon-like peptide-1 on KATP channel-dependent and -independent effects of glucose, sulphonylureas and nateglinide. J Endocrinol 2006, 190:889-96. 10.1677/joe.1.06949, 17003289.
17. Yada T, Itoh K, Nakata M. Glucagon-like peptide-1-(7-36)amide and a rise in cyclic adenosine 3',5'-monophosphate increase cytosolic free Ca2+ in rat pancreatic beta-cells by enhancing Ca2+ channel activity. Endocrinology 1993, 133:1685-92. 10.1210/en.133.4.1685, 8404610.
18. Sakuta H. ATP-sensitive potassium channel and hormone/neuropeptide. Nippon Naibunpi Gakkai Zasshi 1995, 71:579-86.
19. Holz G, Leech CA, Habener JF. Activation of a cAMP-regulated Ca(2+)-signaling pathway in pancreatic beta-cells by the insulinotropic hormone glucagon-like peptide-1. J Biol Chem 1995, 270:17749-57. 10.1074/jbc.270.30.17645, 7543091.
20. Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen YT, et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 2006, 317:1106-13. 10.1124/jpet.106.100982, 16489128.
21. Uesaka T, Yano K, Sugimoto S, Ando M. Glucagon-like peptide isolated from the eel intestine: effects on atrial beating. J Exp Biol 2001, 204:3019-26.
22. Sasaki S, Nakagaki I, Kondo H, Hori S. Involvement of the ryanodine-sensitive Ca2+ store in GLP-1-induced Ca2+ oscillations in insulin-secreting HIT cells. Pflugers Arch 2002, 445:342-51. 10.1007/s00424-002-0965-z, 12466936.
23. Kang G, Chepurny OG, Holz GG. cAMP-regulated guanine nucleotide exchange factor II (Epac2) mediates Ca2+-induced Ca2+ release in INS-1 pancreatic beta-cells. J Physiol 2001, 536:375-85. 10.1111/j.1469-7793.2001.0375c.xd, 2278885, 11600673.
24. Cigaina V, Hirschberg AL. Gastric pacing for morbid obesity: plasma levels of gastrointestinal peptides and leptin. Obes Res 2003, 11:1456-62. 10.1038/oby.2003.195, 14694209.
25. Xiao YF, Gomez AM, Morgan JP, Lederer WJ, Leaf A. Suppression of voltage-gated L-type Ca2+ currents by polyunsaturated fatty acids in adult and neonatal rat ventricular myocytes. Proc Natl Acad Sci USA 1997, 94:4182-7. 10.1073/pnas.94.8.4182, 20596, 9108126.
26. Ke Q, Xiao YF, Bradbury JA, Graves JP, Degraff LM, Seubert JM, et al. Electrophysiological properties of cardiomyocytes isolated from CYP2J2 transgenic mice. Mol Pharmacol 2007, 72:1063-73. 10.1124/mol.107.035881, 2243182, 17652182.
27. Reuter H. Calcium channel modulation by neurotransmitters, enzymes and drugs. Nature 1983, 301:569-74. 10.1038/301569a0, 6131381.
28. McDonald TF, Pelzer S, Trautwein W, Pelzer DJ. Regulation and modulation of calcium channels in cardiac, skeletal, and smooth muscle cells. Physiol Rev 1994, 74:365-507.
29. Keef KD, Hume JR, Zhong J. Regulation of cardiac and smooth muscle Ca(2+) channels (Ca(V)1.2a,b) by protein kinases. Am J Physiol Cell Physiol 2001, 281:C1743-56.
30. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009, 58:975-83. 10.2337/db08-1193, 2661586, 19151200.
31. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005, 54:146-51. 10.2337/diabetes.54.1.146, 15616022.
32. Bose AK, Mocanu MM, Carr RD, Yellon DM. Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovasc Drugs Ther 2007, 21:253-6. 10.1007/s10557-007-6030-6, 17541736.
33. Howell SL, Jones PM, Persaud SJ. Regulation of insulin secretion: the role of second messengers. Diabetologia 1994, 37(Suppl 2):S30-5. 10.1007/BF00400823, 7821737.
34. Ramos LS, Zippin JH, Kamenetsky M, Buck J, Levin LR. Glucose and GLP-1 stimulate cAMP production via distinct adenylyl cyclases in INS-1E insulinoma cells. J Gen Physiol 2008, 132:329-38. 10.1085/jgp.200810044, 2518727, 18695009.
35. Leibowitz MD, Biswas C, Brady EJ, Conti M, Cullinan CA, Hayes NS, et al. A novel insulin secretagogue is a phosphodiesterase inhibitor. Diabetes 1995, 44:67-74. 10.2337/diabetes.44.1.67, 7813816.
36. Holz GG, Leech CA, Heller RS, Castonguay M, Habener JF. cAMP-dependent mobilization of intracellular Ca2+ stores by activation of ryanodine receptors in pancreatic beta-cells. A Ca2+ signaling system stimulated by the insulinotropic hormone glucagon-like peptide-1-(7-37). J Biol Chem 1999, 274:14147-56. 10.1074/jbc.274.20.14147, 10318832.
37. Gomez E, Pritchard C, Herbert TP. cAMP-dependent protein kinase and Ca2+ influx through L-type voltage-gated calcium channels mediate Raf-independent activation of extracellular regulated kinase in response to glucagon-like peptide-1 in pancreatic beta-cells. J Biol Chem 2002, 277:48146-51. 10.1074/jbc.M209165200, 12364324.
38. Britsch S, Krippeit-Drews P, Lang F, Gregor M, Drews G. Glucagon-like peptide-1 modulates Ca2+ current but not K+ATP current in intact mouse pancreatic B-cells. Biochem Biophys Res Commun 1995, 207:33-9. 10.1006/bbrc.1995.1149, 7857285.
39. Suga S, Kanno T, Nakano K, Takeo T, Dobashi Y, Wakui M. GLP-I(7-36) amide augments Ba2+ current through L-type Ca2+ channel of rat pancreatic beta-cell in a cAMP-dependent manner. Diabetes 1997, 46:1755-60. 10.2337/diabetes.46.11.1755, 9356022.
40. Gutniak MK, Svartberg J, Hellstrom PM, Holst JJ, Adner N, Ahren B. Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes. J Intern Med 2001, 250:81-7. 10.1046/j.1365-2796.2001.00862.x, 11454146.
41. Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992, 326:1316-22. 10.1056/NEJM199205143262003, 1348845.
42. Svartberg J, Holst JJ, Gutniak M, Adner N. The ethanol augmentation of glucose-induced insulin secretion is abolished by calcium antagonism with nifedipine: no evidence for a role of glucagon-like peptide-1 (GLP-1). Pancreas 1998, 16:66-71. 10.1097/00006676-199801000-00011, 9436865.
43. Ahren B, Pacini G. Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice. Am J Physiol 1999, 277:E996-E1004.
44. Jacobo SM, Guerra ML, Hockerman GH. Cav1.2 and Cav1.3 are differentially coupled to glucagon-like peptide-1 potentiation of glucose-stimulated insulin secretion in the pancreatic beta-cell line INS-1. J Pharmacol Exp Ther 2009, 331:724-32. 10.1124/jpet.109.158519, 2775263, 19710366.
45. Liu Q, Anderson C, Broyde A, Polizzi C, Fernandez R, Baron A, et al. Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc Diabetol 2010, 9:76. 10.1186/1475-2840-9-76, 2996354, 21080957.
46. Liu Q, Adams L, Broyde A, Fernandez R, Baron AD, Parkes DG. The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats. Cardiovasc Diabetol 2010, 9:32. 10.1186/1475-2840-9-32, 2922097, 20678234.
47. Kim JY, Lim DM, Moon CI, Jo KJ, Lee SK, Baik HW, et al. Exendin-4 protects oxidative stress-induced beta-cell apoptosis through reduced JNK and GSK3beta activity. J Korean Med Sci 2010, 25:1626-32. 10.3346/jkms.2010.25.11.1626, 2967000, 21060752.
48. Eldor R, Kidron M, Greenberg-Shushlav Y, Arbit E. Novel glucagon-like peptide-1 analog delivered orally reduces postprandial glucose excursions in porcine and canine models. J Diabetes Sci Technol 2010, 4:1516-23.